Citations

Clear

174 citation(s) found for "Winham, SJ".

Incorporating Robustness to Imaging Physics into Radiomic Feature Selection for Breast Cancer Risk Estimation
Acciavatti, Raymond J. , Cohen, Eric A. , Gastounioti, Aimilia , Pantalone, Lauren , Vachon, Celine M. , Gastounioti, Aimilia , Vachon, Celine, Acciavatti, Raymond J , Maghsoudi, Omid Haji , Hsieh, Meng-Kang, Conant, Emily F. , Scott, Christopher G. , Winham, Stacey J. , Kerlikowske, Karla , Vachon, Celine M. , Maidment, Andrew D. A. , Kontos, Despina

Mayo Clinic

Cancers | November 1, 2021 | Volume: 13 | Issue: 21 | Pages: 5497

10.3390/cancers13215497 | PMID 34771660 Get It

Digital mammography has seen an explosion in the number of radiomic features used for risk-assessment modeling. However, having more features is not necessarily beneficial, as some features may be overly sensitive to imaging physics (contrast, noise, and image sharpness). To measure the effects of imaging physics, we analyzed the feature variation across imaging acquisition settings (kV, mAs) using an anthropomorphic phantom. We also analyzed the intra-woman variation (IWV), a measure of how much a feature varies between breasts with similar parenchymal patterns—a woman’s left and right breasts. From 341 features, we identified “robust” features that minimized the effects of imaging physics and IWV. We also investigated whether robust features offered better case-control classification in an independent data set of 575 images, all with an overall BI-RADS® assessment of 1 (negative) or 2 (benign); 115 images (cases) were of women who developed cancer at least one year after that screening image, matched to 460 controls. We modeled cancer occurrence via logistic regression, using cross-validated area under the receiver-operating-characteristic curve (AUC) to measure model performance. Models using features from the most-robust quartile of features yielded an AUC = 0.59, versus 0.54 for the least-robust, with p < 0.005 for the difference among the quartiles.
DNA Methylation Profiles of Ovarian Clear Cell Carcinoma
Cunningham, Julie M. , Winham, Stacey J. , Wang, Chen , Weiglt, Britta, Fu, Zhuxuan, Armasu, Sebastian M., McCauley, Bryan M., Brand, Alison H., Chiew, Yoke-Eng , Elishaev, Esther, Gourley, Charlie , Kennedy, Catherine J. , Laslavic, Angela, Lester, Jenny, Piskorz, Anna, Sekowska, Magdalena, Brenton, James D. , DeFazio, Anna , Drapkin, Ronny , Huntsman, David G., Köbel, Martin , Konner, Jason, Lawrenson, Kate , Papaemmanuil, Elli, Bolton, Kelly L., Goode, Ellen L., Brand, Alison H. , Fu, Zhuxuan , Churchman, Michael , Fazio, Anna de , Drapkin, Ronny , Elias, Kevin M , Karlan, Beth Y , Köbel, Martin , Lawrenson, Kate , Modugno, Francesmary , Winham, Stacey J , Brenton, James D , Wang, Chen , Kennedy, Catherine J , Fu, Zhuxuan , Brand, Alison H , Chiew, Yoke-Eng , Cunningham, Julie M , Weiglt, Britta, Fu, Zhuxuan, Armasu, Sebastian M., McCauley, Bryan M., Brand, Alison H., Elishaev, Esther, Gourley, Charlie , Laslavic, Angela, Lester, Jenny, Piskorz, Anna, Sekowska, Magdalena, Huntsman, David G., Konner, Jason, Papaemmanuil, Elli, Bolton, Kelly L., Goode, Ellen L.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | October 25, 2021 | Volume: 31 | Issue: 1 | Pages: 132-141

10.1158/1055-9965.epi-21-0677 | PMID 34697060 Get It

Abstract Background: Ovarian clear cell carcinoma (OCCC) is a rare ovarian cancer histotype that tends to be resistant to standard platinum-based chemotherapeutics. We sought to better understand the role of DNA methylation in clinical and biological subclassification of OCCC. Methods: We interrogated genome-wide methylation using DNA from fresh frozen tumors from 271 cases, applied nonsmooth nonnegative matrix factorization (nsNMF) clustering, and evaluated clinical associations and biological pathways. Results: Two approximately equally sized clusters that associated with several clinical features were identified. Compared with Cluster 2 (N = 137), Cluster 1 cases (N = 134) presented at a more advanced stage, were less likely to be of Asian ancestry, and tended to have poorer outcomes including macroscopic residual disease following primary debulking surgery (P &lt; 0.10). Subset analyses of targeted tumor sequencing and IHC data revealed that Cluster 1 tumors showed TP53 mutation and abnormal p53 expression, and Cluster 2 tumors showed aneuploidy and ARID1A/PIK3CA mutation (P &lt; 0.05). Cluster-defining CpGs included 1,388 CpGs residing within 200 bp of the transcription start sites of 977 genes; 38% of these genes (N = 369 genes) were differentially expressed across cluster in transcriptomic subset analysis (P &lt; 10−4). Differentially expressed genes were enriched for six immune-related pathways, including IFNα and IFNγ responses (P &lt; 10−6). Conclusions: DNA methylation clusters in OCCC correlate with disease features and gene expression patterns among immune pathways. Impact: This work serves as a foundation for integrative analyses that better understand the complex biology of OCCC in an effort to improve potential for development of targeted therapeutics.
Genome-wide Interaction Analysis of Menopausal Hormone Therapy Use and Breast Cancer Risk among 62,370 Women
Kapoor, Pooja, Auer, Paul, Dennis, Joe, Wang, Qin , Bolla, Manjeet K. , Aronson, Kristan J. , Lee, Derrick , Cordina‐Duverger, Emilie, Mulot, Claire , Teras, Lauren R., Patel, Alpa V. , Hoppe, Reiner , Lo, Wing‐Yee, Brüning, Thomas , Hamann, Ute, Couch, Fergus, Ruddy, Kathryn J. , MacInnis, Robert J. , Wilkens, Lynne, Haiman, Christopher A. , Krüger, Ute , Wagner, Philippe , Vachon, Celine M. , Eliassen, Heather, Andrulis, Irene L. , Evans, D. Gareth , Ziogas, Argyrios, Orr, Nick , Linet, Martha S. , Prentice, Ross L. , Easton, Douglas F. , Chang‐Claude, Jenny , Lindström, Sara , Evans, D Gareth , Maclnnis, Robert , Orr, Nick , Wang, Xiaoliang , Kapoor, Pooja, Dunning, Alison M. , Lush, Michael J. , Michailidou, Kyriaki , Murphy, Rachel A. , Brooks‐Wilson, Angela , Guénel, Pascal , Truong, Thérèse , Teras, Lauren R. , Dossus, Laure , Kaaks, Rudolf , Czene, Kamila , Gabrielson, Marike , Hall, Per N , Eriksson, Mikael , Jung, Audrey , Becher, Heiko , Couch, Fergus J. , Larson, Nicole, Olson, Janet E. , Giles, Graham G. , Southey, Melissa C. , Marchand, Loı̈c Le , Wilkens, Lynne R. , Olsson, Håkan , Augustinsson, Annelie , Scott, Christopher, Winham, Stacey J. , Vachon, Celine M. , Perou, Charles M. , Olshan, Andrew F. , Troester, Melissa A. , Hunter, David, Eliassen, A. Heather , Tamimi, Rulla M. , Brantley, Kristen D. , Figueroa, Jonine D. , Chanock, Stephen Jacob , Ahearn, Thomas U. , García‐Closas, Montserrat , Newman, William G. , Veen, Elke M. van , Howell, Anthony , Wolk, Alicja , Håkansson, Niclas , Anton‐Culver, Hoda , Jones, Michael E. , Schoemaker, Minouk J. , Swerdlow, Anthony J. , Kitahara, Cari M. , Milne, Roger L. , Kraft, Peter

Mayo Clinic

No container title available | July 2, 2021 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-532921/v2 Get It

Abstract Background: Use of menopausal hormone therapy (MHT) is associated with increased risk for breast cancer. However, the relevant mechanisms and its interaction with genetic variants are not fully understood. Methods: We conducted a genome-wide interaction analysis between MHT use and genetic variants for breast cancer risk in 27,585 cases and 34,785 controls from 26 observational studies. All women were post-menopausal and of European ancestry. Multivariable logistic regression models were used to test for multiplicative interactions between genetic variants and current MHT use. We considered interaction p-values<5x10-8 as genome-wide significant, and p-values<1x10-5 as suggestive. Linkage disequilibrium (LD)-based clumping was performed to identify independent candidate variants.Results: None of the 9.7 million genetic variants tested for interactions with MHT use reached genome-wide significance. Only 213 variants, representing 18 independent loci, had p-values<1x105. The strongest evidence was found for rs4674019 (p-value=2.27x10-7), which showed genome-wide significant interaction (p-value=3.8x10-8) with current MHT use when analysis was restricted to population-based studies only. Limiting the analyses to combined estrogen-progesterone MHT use only or to estrogen receptor (ER) positive cases did not identify any genome-wide significant evidence of interactions. Conclusions: In this large genome-wide SNP-MHT interaction study of breast cancer, we found no strong support for common genetic variants modifying the effect of MHT on breast cancer risk. These results suggest that common genetic variation has limited impact on the observed MHT–breast cancer risk association.
Abstract 2600: Deep-LIBRA: An artificial intelligence approach for fully-automated assessment of breast density in digital mammography
Christopher, Scott, Pantalone, Lauren , Wu, Fangfang , Cohen, Eric A. , Stacey, Winham, Vachon, Celine M. , Maghsoudi, Omid Haji , Scott, Christopher, Gastounioti, Aimilia , Wu, Fang-Fang, Conant, Emily F. , Vachon, Celine M. , Kontos, Despina

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: 2600-2600

10.1158/1538-7445.am2021-2600 Get It

Abstract Accurate estimation of mammographic breast density could aid in augmenting breast cancer risk assessment for women undergoing breast screening with full-field digital mammography (FFDM). Breast density can be estimated from FFDM and is most commonly assessed in the clinic by visual grading into one of the four categories defined by the American College of Radiology BI-RADS. However, BI-RADS density assessment is highly subjective and does not provide a quantitative, continuous measure of percent density (PD), which would allow for more refined risk stratification and assessment of density changes. Here, we introduce Deep-LIBRA, an artificial intelligence (AI) tool for fully-automated assessment of breast PD from FFDM images. Two key modules form the core of Deep-LIBRA: 1) an implementation of a modified U-Net architecture for breast segmentation and 2) a radiomic machine learning module that performs PD estimation within the segmented breast region. To develop and validate Deep-LIBRA, raw (i.e., "For Processing") FFDM images (Selenia Dimensions, Hologic Inc.) acquired at two breast cancer screening practices were retrospectively analyzed. For the breast segmentation module, we used a total of 12,100 FFDM studies from 2,200 individual women and a 90%-10% split-sample training-validation approach, using the Dice coefficient to evaluate the accuracy of Deep-LIBRA versus ground-truth manual breast segmentation. For the PD estimation module we used a total of 3,304 FFDM images from 1,652 individual women; manual PD scores obtained with the widely used Cumulus software were used as the "gold standard" in a three-fold cross-validation setting to assess the accuracy of Deep-LIBRA in PD estimation. PD estimates from Deep-LIBRA were also compared with breast density estimates from the commercially available Volpara software. Breast segmentation had a Dice coefficient of 95.31% when compared to ground-truth manual breast segmentation in the validation set. Deep-LIBRA average differences from ground-truth PD scores in the three cross-validation folds were 4.91%, 4.65%, and 4.22%, while Volpara had corresponding average differences of 6.20%, 6.01%, and 5.94%. Deep-LIBRA PD scores were also significantly different from Volpara PD (t-test p-value &lt; 0.001 in all three folds). Preliminary evaluation results show that Deep-LIBRA is a promising AI approach for accurately assessing PD from FFDM images. Citation Format: Omid Haji Maghsoudi, Scott Christopher, Aimilia Gastounioti, Lauren Pantalone, Fang-Fang Wu, Eric A. Cohen, Winham Stacey, Emily F. Conant, Celine Vachon, Despina Kontos. Deep-LIBRA: An artificial intelligence approach for fully-automated assessment of breast density in digital mammography [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2600.
Abstract 2274: Somatic variant burdenin benign breast disease and association with risk of subsequent breast cancer
Cunningham, Julie M. , Liu, Yuanhang , Bhagwate, Aditya , Heinzen, Ethan P. , McDonough, Samantha J., Winham, Stacey J. , Stallings‐Mann, Melody , Vierkant, Robert A. , Carter, Jodi M. , Sherman, Mark E. , Radisky, Derek C. , Degnim, Amy C. , Wang, Chen

Mayo Clinic

Cancer Research | July 1, 2021 | Volume: 81 | Issue: 13_Supplement | Pages: 2274-2274

10.1158/1538-7445.am2021-2274 Get It

Abstract Benign breast disease (BBD) is an established risk factor for development of breast cancer (BC). However, little is known about the prevalence of somatic genetic alterations at the time of BBD diagnosis and relationship to subsequent BC. To characterize DNA variants in BBD and investigate association with BC risk, we isolated DNA from formalin-fixed paraffin-embedded (FFPE) BBD biopsies and assessed mutations using a panel of 93 breast cancer predisposition genes (Qiagen GeneRead). The study set consisted of 120 BBD patients from three age-matched groups defined based on 16 years of BC follow-up: BBD-controls (cancer-free after 16 years), BBD-ER+, or BBD-ER- breast cancer (within 16 years). Bioinformatics quality checks included comparisons of paired fresh-frozen and FFPE replicates to reduce false variant calls induced by FFPE artifacts. Gene-level variant burden differences among study groups were assessed using 12 statistical approaches, adjusted for patient age, year of biopsy, and histology. To investigate possible immune implications of increased variant burden, extent of leukocytes in the BBD biopsies was assessed using CD45 immunohistochemistry. To assess variant profile changes during the progression from BBD to BC, we also performed targeted sequencing of 12 BBD-matched subsequent tumor samples (six ER+ and six ER-) developed within 5 years of BBD diagnosis. Gene-level association results showed consistently skewed distributions suggesting a higher variant burden in BBD controls: among the top 10 genes associated with case-status (p&lt;0.05), all had BC-risk odds ratio estimates less than 1.0. Immune infiltrates, assessed by CD45 H-scores, were positively associated with overall variant burden (r=0.42, p=0.0031), and noticeably higher in cancer-free controls (r=0.50, p=0.005). Comparison of mutation variants in 12 BBD cases that developed cancer within 5 years of diagnosis and their subsequent tumors revealed that more than half of the non-SNP variants were shared between the BBD and the subsequent tumor (54.6%), whereas less than one quarter were unique to the tumor (20.6%) or unique to the BBD (24.9%). Through BBD-BC paired variant analysis, three subjects were found with newly emergent clones uniquely appearing in the tumors and four subjects had loss of clones in the tumor that were present in the BBD. These results show that somatic variant burden is lower in patients with BBD that progress to BC, mutation profiles of BC progression are heterogeneous, and BBD tissues with reduced variant burden also show reduced immune infiltrate. This implicates a potential protective role for immune activation in BBD. Future directions will define the characteristics of the potentially protective immune response and its role in variant heterogeneity in a larger sample set, integrated with paired RNA sequencing to better understand the pathways involved and the relationship to immune infiltration. Citation Format: Stacey J. Winham, Julie M. Cunningham, Yuanhang Liu, Aditya V. Bhagwate, Ethan P. Heinzen, Samantha J. McDonough, Melody L. Stallings-Mann, Robert A. Vierkant, Jodi M. Carter, Mark E. Sherman, Derek C. Radisky, Amy C. Degnim, Chen Wang. Somatic variant burdenin benign breast disease and association with risk of subsequent breast cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2021; 2021 Apr 10-15 and May 17-21. Philadelphia (PA): AACR; Cancer Res 2021;81(13_Suppl):Abstract nr 2274.
Identification of a Locus Near ULK1 Associated With Progression-Free Survival in Ovarian Cancer
Quinn, Michael C. , McCue, Karen, Shi, Wei , Johnatty, Sharon E. , Beesley, Jonathan, Civitarese, Andrew, O’Mara, Tracy A. , Glubb, Dylan M. , Armasu, Sebastian M. , Ong, Jue‐Sheng , Lu, Yi , Gao, Bo , Patch, Ann‐Marie , Fasching, Peter A. , Beckmann, Matthias W. , Lambrechts, Diether , Vergote, Ignace , Beeghly‐Fadiel, Alicia, García, María J. , Goodman, Marc T. , Dörk, Thilo , Moysich, Kirsten B. , Pfisterer, Jacobus , Bauman, Klaus, Lester, Jenny , Cunningham, Julie M. , McCauley, Bryan M. , Høgdall, Claus , Schildkraut, Joellen M. , Riggan, Marjorie J. , Terry, Kathryn L. , Webb, Penelope M. , May, Taymaa, Ene, Gabrielle, Huntsman, David G., Woo, Michelle, Carney, Michael E. , Fereday, Sián , Kennedy, Catherine J. , Edwards, Stacey L. , DeFazio, Anna , Goode, Ellen L. , MacGregor, Stuart , Chenevix‐Trench, Georgia , Lambrechts, Diether , Quinn, Michael C J , Ong, Jue-Sheng , Gharahkhani, Puya , Lu, Yi , Fasching, Peter A , Lambrechts, Diether , Vergote, Ignace , Dörk, Thilo , Dürst, Matthias , Modugno, Francesmary , Bois, Andreas du , Karlan, Beth Y , Cunningham, Julie M , Kjaer, Susanne K , Webb, Penelope M , Friedlander, Michael , Glasspool, Rosalind , Hinsley, Samantha , Heitz, Florian , Kennedy, Catherine J , Winham, Stacey J , Fazio, Anna de , Pharoah, Paul D P , MacGregor, Stuart , Lambrechts, Diether , Moysich, Kirsten , O'Mara, Tracy A , Chenevix-Trench, Georgia , Høgdall, Claus K , Fereday, Sian , Goodman, Marc T , Beesley, Jonathan, Tyrer, Jonathan P. , Gharahkhani, Puya , Edwards, Digna R. Velez , Beeghly‐Fadiel, Alicia , Benı́tez, Javier , Modugno, Francesmary , Karlan, Beth Y. , Larson, Melissa C. , Kjær, Susanne K. , Jensen, Allan , Høgdall, Estrid , Berchuck, Andrew , Cramer, Daniel W. , Bjørge, Line , Friedländer, Michael , Pejovic, Tanja B. , Moffitt, Melissa , Glasspool, Rosalind , Heitz, Florian , Winham, Stacey J. , Pharoah, Paul D.P.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | June 23, 2021 | Volume: 30 | Issue: 9 | Pages: 1669-1680

10.1158/1055-9965.epi-20-1817 | PMID 34162658 Get It

Abstract Background: Many loci have been found to be associated with risk of epithelial ovarian cancer (EOC). However, although there is considerable variation in progression-free survival (PFS), no loci have been found to be associated with outcome at genome-wide levels of significance. Methods: We carried out a genome-wide association study (GWAS) of PFS in 2,352 women with EOC who had undergone cytoreductive surgery and standard carboplatin/paclitaxel chemotherapy. Results: We found seven SNPs at 12q24.33 associated with PFS (P &lt; 5 × 10–8), the top SNP being rs10794418 (HR = 1.24; 95% CI, 1.15–1.34; P = 1.47 × 10–8). High expression of a nearby gene, ULK1, is associated with shorter PFS in EOC, and with poor prognosis in other cancers. SNP rs10794418 is also associated with expression of ULK1 in ovarian tumors, with the allele associated with shorter PFS being associated with higher expression, and chromatin interactions were detected between the ULK1 promoter and associated SNPs in serous and endometrioid EOC cell lines. ULK1 knockout ovarian cancer cell lines showed significantly increased sensitivity to carboplatin in vitro. Conclusions: The locus at 12q24.33 represents one of the first genome-wide significant loci for survival for any cancer. ULK1 is a plausible candidate for the target of this association. Impact: This finding provides insight into genetic markers associated with EOC outcome and potential treatment options. See related commentary by Peres and Monteiro, p. 1604
Mammographic Variation Measures, Breast Density, and Breast Cancer Risk
Heine, John , Fowler, Erin , Jensen, Matthew R. , Brandt, Kathleen R. , Wu, Fang , Miglioretti, Diana L. , Vachon, Celine M. , Wu, Fang F, Miglioretti, Diana L , Scott, Christopher G. , Shepherd, John , Hruska, Carrie B. , Winham, Stacey J. , Norman, Aaron D. , Pankratz, V. Shane , Kerlikowske, Karla , Vachon, Celine M.

Mayo Clinic

American Journal of Roentgenology | June 23, 2021 | Volume: 217 | Issue: 2 | Pages: 326-335

10.2214/ajr.20.22794 | PMID 34161135 Get It

Randomized, Double-Blind Trial on the Impact of Word Count in Cancer Clinical Trial Consent Forms
Almodallal, Yahya , Duong, Quyen, Satele, Daniel , Novotny, Paul J. , Cook, Kathryn , Chauhan, Cynthia, Daiss, Michelle K., Le‐Rademacher, Jennifer , Looker, Sherry, Martin, Nichole , Smestad, Michanda F., Mandrekar, Sumithra J. , Jatoi, Aminah , Novotny, Paul, Cook, Kathryn D , Mandrekar, Sumithra J , Jatoi, Aminah , Le-Rademacher, Jennifer G , Winham, Stacey J.

Mayo Clinic

JCO Oncology Practice | June 14, 2021 | Volume: 17 | Issue: 10 | Pages: e1460-e1472

10.1200/op.21.00071 | PMID 34125586 Get It

PURPOSE:This randomized, double-blind study sought to understand whether cancer clinical trial consent form verbosity detracts from patients' decision making on trial enrollment.METHODS:This trial tested mock consent forms of 2,000, 4,000, and 6,000 words. The first two comprised the two experimental arms and the third the control arm. Phase II was conducted to identify the promising arm, which, in phase III, was compared with the control arm. Each consent form described the same trial. Eligible adult patients reported a cancer history and English literacy. The primary end point used a patient-reported Likert scale to assess the relationship between information in the consent form and trial decision making.RESULTS:In phase II, 93 patients were accrued and prompted the selection of the 2,000-word consent form for phase III. In phase III, 182 patients were recruited, resulting in 240 total evaluable patients to compare the 2,000-word versus the 6,000-word arm (control). For the primary end point, 103 (84%) and 107 (91%) patients in the 2,000- and 6,000-word arms, respectively, strongly agreed or agreed with the following: “The information in this consent form helped me make a decision about whether or not to enroll in the trial” (two-sided, P = .14). Median time to read each consent form was 8 and 12 minutes, respectively (two-sided, P < .0001). Among those assigned these consent forms, 84% and 73%, respectively (two-sided, P = .04) signed or expressed a willingness to sign.CONCLUSION:This study's primary end point was not met. However, secondary outcomes suggest a need to further study the efficiency and efficacy of shorter consent forms for cancer clinical trial enrollment.
Testing and estimation of X‐chromosome SNP effects: Impact of model assumptions
Song, Yilin , Biernacka, Joanna M. , Winham, Stacey J. , Winham, Stacey J , Biernacka, Joanna

Mayo Clinic

Genetic Epidemiology | June 3, 2021 | Volume: 45 | Issue: 6 | Pages: 577-592

10.1002/gepi.22393 | PMID 34082482 Get It

AbstractInterest in analyzing X chromosome single nucleotide polymorphisms (SNPs) is growing and several approaches have been proposed. Prior studies have compared power of different approaches, but bias and interpretation of coefficients have received less attention. We performed simulations to demonstrate the impact of X chromosome model assumptions on effect estimates. We investigated the coefficient biases of SNP and sex effects with commonly used models for X chromosome SNPs, including models with and without assumptions of X chromosome inactivation (XCI), and with and without SNP–sex interaction terms. Sex and SNP coefficient biases were observed when assumptions made about XCI and sex differences in SNP effect in the analysis model were inconsistent with the data‐generating model. However, including a SNP–sex interaction term often eliminated these biases. To illustrate these findings, estimates under different genetic model assumptions are compared and interpreted in a real data example. Models to analyze X chromosome SNPs make assumptions beyond those made in autosomal variant analysis. Assumptions made about X chromosome SNP effects should be stated clearly when reporting and interpreting X chromosome associations. Fitting models with SNP × Sex interaction terms can avoid reliance on assumptions, eliminating coefficient bias even in the absence of sex differences in SNP effect.